AREN1721, a randomized phase 2 trial of axitinib+nivolumab combination therapy vs. single agent nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups, an NCI National Clinical Trials Network (NCTN) phase 2 study.
Nicholas G. Cost(University of Colorado Denver), James I. Geller(Cincinnati Children's Hospital Medical Center), Ana M. Molina(Cornell University), Lindsay A. Renfro(Mayo Clinic in Arizona), John A. Kalapurakal(Northwestern University), Luke Pater(University of Cincinnati), Mamta Parikh(UC Davis Comprehensive Cancer Center), Matthew R. Zibelman(Fox Chase Cancer Center), Elizabeth A. Mullen(United States National Library of Medicine), Peter F. Ehrlich(University of Michigan), Jeffrey S. Dome(Children's National), Elisabeth T. Tracy(University of North Carolina at Chapel Hill), Ian Tfirn(University of Florida)
Cited by 7
Related Papers
<sup>Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2017|357
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
|PubMed|2003|198
Hereditary Folate Malabsorption
|Medicine|2002|135
Molecular Characterization of the Pediatric Preclinical Testing Panel
|Clinical Cancer Research|2008|120
Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy
|Journal of Clinical Investigation|2003|118